Clinical

Dataset Information

0

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours


ABSTRACT: This is a Phase I, open-label, multi-centre, drug combination study of double and triple combination oral selumetinib (AZD6244 Hyd-sulfate) plus intravenous (IV) MEDI4736 and oral selumetinib plus IV MEDI4736 and IV tremelimumab in patients with advanced solid tumours.

DISEASE(S): Head And Neck Carcinoma,Lung Cancer,Pancreatic Adenocarcinoma,Biliary Tract Cancer,Biliary Tract Neoplasms,Melanoma,Colorectal Cancer,Gastroesophageal Cancer,Breast Cancer

PROVIDER: 2200961 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2021-09-12 | GSE183859 | GEO
2021-03-23 | GSE168602 | GEO
| PRJNA712989 | ENA
2021-03-23 | GSE168603 | GEO
| 2154156 | ecrin-mdr-crc
| 2088566 | ecrin-mdr-crc
2023-07-05 | GSE235919 | GEO
2023-07-05 | GSE235917 | GEO
2024-10-07 | GSE277520 | GEO
2017-02-15 | GSE94873 | GEO